Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap, S.Demirci, U.Bugdayci, F.Tural, D.Korkmaz, T.Paydas, S.Yilmaz, C.2024-04-242024-04-2420191556-08641556-1380https://doi.org/10.1016/j.jtho.2019.08.1166https://hdl.handle.net/11468/15784[Abstract Not Available]eninfo:eu-repo/semantics/openAccessAlk PositiveRos1 PositiveLorlatinibAdvanced Stage Lung CancerLorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in TurkeyConference Object1410S558S559WOS:00049216220308210.1016/j.jtho.2019.08.1166Q1